Key result
Cryoballoon ablation reduces median AF burden to ~1% at three years despite common late recurrences.
Its licence doesn't allow us to show a copy here.
Why the study?
Long-term rhythm outcomes following cryoballoon ablation in early persistent AF remain incompletely characterized.
Does cryoballoon ablation reduce AF burden over 3 years in patients with early persistent AF?
Does cryoballoon ablation reduce AF burden over 3 years in patients with early persistent AF?
Cryoballoon ablation provides durable suppression of AF burden over 3 years in early persistent AF, though late, predominantly paroxysmal recurrences are common and best detected by continuous monitoring.
May support durable AF burden reduction after cryoballoon ablation; leaves open need for RCTs versus medical therapy.
BACKGROUND: Long-term rhythm outcomes following cryoballoon ablation (CBA) in early persistent atrial fibrillation (AF) remain incompletely characterized. OBJECTIVE: To evaluate 3-year AF burden trajectories, subsequent recurrence patterns detected by implantable loop recorder (ILR), and association with healthcare resource utilization (HCRU). METHODS: The COOL-PER trial was a prospective, multicenter, single-arm study enrolling patients with early persistent AF (duration ≤3 years). An ILR was implanted 7-90 days before CBA for continuous rhythm monitoring. RESULTS: Among 130 enrolled patients, 123 completed 3-year follow-up (mean age 60.5±8.4 years; 25.2% female). Median AF burden decreased from 99.9% [IQR 53.1-100.0] at baseline to 0.1% [0.0-4.2], 0.5% [0.0-9.1], and 0.7% [0.0-9.5] at 1, 2, and 3 years (all P<0.001). Of 47 patients recurrence-free at 1 year, 25 (53.2%) developed subsequent recurrence, and 20 (80.0%) detected by ILR alone. Compared with first-year recurrence, subsequent recurrence was less often persistent (4.0% vs 28.9%; P=0.001) with lower AF burden (0.1% [0.0-1.6] vs 2.8% [0.4-18.7]; P=0.010). Persistent-type recurrence and AF burden ≥10% were both associated with more additional rhythm control interventions (78.3% vs. 30.8% vs. 0%; 78.6% vs. 39.1% vs. 0%; both P<0.001) and cardiovascular hospitalization (17.4% vs. 3.8% vs. 0%, P=0.045; 14.3% vs. 4.3% vs. 0%, P=0.029). CONCLUSIONS: CBA achieved durable AF burden suppression over 3-years in early persistent AF. Subsequent recurrence after the first year was common, predominantly detectable by ILR only. Subsequent recurrences were often paroxysmal with lower AF burden and associated with lower HCRU, supporting the value of continuous long-term rhythm monitoring for characterizing rhythm status beyond the first post-ablation year.
No takes yet. Share an insight, caveat, or question.
Han et al. (2026) studied Early persistent atrial fibrillation (AF) (n=130). Cryoballoon ablation (CBA) was evaluated on Median AF burden at 3 years (p=<0.001). Cryoballoon ablation significantly reduced median AF burden from 99.9% at baseline to 0.7% at 3 years (P<0.001), though subsequent recurrences after the first year were common.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: